NO20005351L - Paroxetine 10-camphor sulfonate for the treatment of CNS disorders - Google Patents

Paroxetine 10-camphor sulfonate for the treatment of CNS disorders

Info

Publication number
NO20005351L
NO20005351L NO20005351A NO20005351A NO20005351L NO 20005351 L NO20005351 L NO 20005351L NO 20005351 A NO20005351 A NO 20005351A NO 20005351 A NO20005351 A NO 20005351A NO 20005351 L NO20005351 L NO 20005351L
Authority
NO
Norway
Prior art keywords
paroxetine
treatment
cns disorders
camphor sulfonate
camphor
Prior art date
Application number
NO20005351A
Other languages
Norwegian (no)
Other versions
NO20005351D0 (en
Inventor
Michael Urquhart
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20005351D0 publication Critical patent/NO20005351D0/en
Publication of NO20005351L publication Critical patent/NO20005351L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Paroksetin 10-kamfersulfonater er anvendelige ved behandling av visse CNS-lidelser.Paroxetine 10-camphor sulfonates are useful in the treatment of certain CNS disorders.

NO20005351A 1998-04-25 2000-10-24 Paroxetine 10-camphor sulfonate for the treatment of CNS disorders NO20005351L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808894.1A GB9808894D0 (en) 1998-04-25 1998-04-25 Novel compound
PCT/GB1999/001246 WO1999055699A1 (en) 1998-04-25 1999-04-23 Paroxetine 10-camphorsulfonate for treatment of cns disorders

Publications (2)

Publication Number Publication Date
NO20005351D0 NO20005351D0 (en) 2000-10-24
NO20005351L true NO20005351L (en) 2000-10-24

Family

ID=10831007

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005351A NO20005351L (en) 1998-04-25 2000-10-24 Paroxetine 10-camphor sulfonate for the treatment of CNS disorders

Country Status (18)

Country Link
EP (1) EP1076659A1 (en)
JP (1) JP2002513020A (en)
KR (1) KR20010042929A (en)
CN (1) CN1306530A (en)
AP (1) AP2000001958A0 (en)
AU (1) AU3618699A (en)
BG (1) BG104973A (en)
BR (1) BR9909878A (en)
CA (1) CA2329913A1 (en)
EA (1) EA200001105A1 (en)
GB (1) GB9808894D0 (en)
HU (1) HUP0102298A2 (en)
IL (1) IL139018A0 (en)
NO (1) NO20005351L (en)
PL (1) PL343596A1 (en)
SK (1) SK15902000A3 (en)
TR (1) TR200003083T2 (en)
WO (1) WO1999055699A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100672184B1 (en) 2004-09-21 2007-01-19 주식회사종근당 Choline or Choline Derivative Salts of Paroxetine
CN104402708A (en) * 2014-12-07 2015-03-11 河南领先科技药业有限公司 Production method for sodium camphorate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
HU221921B1 (en) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzyl-piperidine or tetrahydro-pyridine derivatives and processes for producing them

Also Published As

Publication number Publication date
NO20005351D0 (en) 2000-10-24
WO1999055699A1 (en) 1999-11-04
BG104973A (en) 2001-09-28
PL343596A1 (en) 2001-08-27
CN1306530A (en) 2001-08-01
BR9909878A (en) 2000-12-26
TR200003083T2 (en) 2001-02-21
EA200001105A1 (en) 2001-04-23
AU3618699A (en) 1999-11-16
GB9808894D0 (en) 1998-06-24
IL139018A0 (en) 2001-11-25
KR20010042929A (en) 2001-05-25
JP2002513020A (en) 2002-05-08
HUP0102298A2 (en) 2002-05-29
SK15902000A3 (en) 2001-05-10
AP2000001958A0 (en) 2000-12-31
CA2329913A1 (en) 1999-11-04
EP1076659A1 (en) 2001-02-21

Similar Documents

Publication Publication Date Title
NO20012995L (en) Compounds useful for the treatment of inflammatory diseases
DK1112106T3 (en) Serotonergic 5HT2 agonists for the treatment of glaucoma
IT1295072B1 (en) PROCEDURE FOR THE PRODUCTION OF STYRENE
EP0972748A4 (en) PROCESS FOR THE MANUFACTURE OF PSEUDO-BOHEMITE
BR0107801B1 (en) process for treating slag or mixtures of slag.
ID27214A (en) TRIAZOLOPIRIDINA FOR TREATMENT OF TROMBOSIS DISORDERS
IT1317751B1 (en) POLYOLEFINS OF METALLOCENE STABILIZED.
NO20003211D0 (en) Triazine compounds for the treatment of CNS disorders
ECSP003590A (en) CALCIOLITIC COMPOUNDS
DE60133385D1 (en) (+) - ALPHA- (2,3-DIMETHOXYPHENYL) -1- (2- (4-FLUORO-PHENYL) ETHYL) -4-PIPERIDINETHANOL OR PRODRUG THEREOF FOR THE TREATMENT OF DAMAGE SYMPTOMS OR COGNITIVE DISORDERS
NO20011892L (en) 3-tetrahydropyridin-4-yl indoles for the treatment of psychotic disorders
SG148840A1 (en) Indole derivatives useful for the treatment of cns disorders
NO991675D0 (en) Process for the alkylation of hindered sulfonamides
NO990450D0 (en) Treatment of mental disorders
BR0107826B1 (en) process for making dust or mixtures of dust.
NO20003481D0 (en) Procedure for the treatment of COPD
DK1200447T3 (en) Oxazinocarbazoles for the treatment of CNS diseases
NO20005352L (en) ascorbate
ID21920A (en) 4-6-FLUORO- (1H) -INDOL-3-IL-1,2,3,6-TETRAH HYDROPIRINS SUBSTITUTED FOR TREATMENT OF CNS INTERFERENCE
NO20005351D0 (en) Paroxetine 10-camphor sulfonate for the treatment of CNS disorders
NO20026029D0 (en) Indole derivatives useful for the treatment of CNS disorders
PT1088010E (en) PRODUCTION OF POLYOLEFINS
NO20026028L (en) Indole derivatives useful for the treatment of CNS disorders
NO20006383L (en) Process of treatment
FR2818747B1 (en) SIAH-NUMB INTERACTION SCREENING METHOD

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application